SpringWorks Therapeutics to Report Second Quarter 2024 Financial Results on Wednesday, August 7, 2024

STAMFORD, Conn., July 23, 2024 (GLOBE NEWSWIRE) — SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Wednesday, August 7, 2024 to report its second quarter financial results and discuss recent business updates.

To join the live webcast and view the corresponding slides, please click here. To participate in the live conference call by phone, please click here to pre-register. Registered participants will then be provided with a dial-in number and conference code to access the call. A replay of the webcast will be available for a limited time following the event on the Investors & Media section of the Company’s website at https://ir.springworkstx.com.

About SpringWorks Therapeutics

SpringWorks is a commercial-stage biopharmaceutical company applying a precision medicine approach to developing and delivering life-changing medicines for people with severe rare diseases and cancer. OGSIVEO® (nirogacestat), approved in the United States for the treatment of adult patients with progressing desmoid tumors who require systemic treatment, is the Company’s first FDA-approved therapy. SpringWorks also has a diversified targeted therapy pipeline spanning solid tumors and hematological cancers, with programs ranging from preclinical development through advanced clinical trials. In addition to its wholly owned programs, SpringWorks has also entered into multiple collaborations with innovators in industry and academia to unlock the full potential for its portfolio and create more solutions for patients in need.

For more information, visit www.springworkstx.com and follow @SpringWorksTx on X (formerly Twitter), LinkedIn, and YouTube.

Contacts:
Kim Diamond
Vice President, Communications and Investor Relations
Phone: 203-561-1646
Email: kdiamond@springworkstx.com

Samantha Hilson Sandler
Senior Director, Investor Relations
Phone: 203-461-5501
Email: samantha.sandler@springworkstx.com

Staff

Recent Posts

Camber Spine Receives FDA Clearance for SPIRA-A Integrated Fixation System

KING OF PRUSSIA, Pa.--(BUSINESS WIRE)--#3dPrinting--Camber Spine, a leading innovator in spine and medical technologies, announced…

1 hour ago

Federman & Sherwood Investigates Burr & Forman LLP for Data Breach

OKLAHOMA CITY--(BUSINESS WIRE)--#BurrForman--The law firm of Federman & Sherwood has initiated an investigation into Burr…

1 hour ago

Maverick Medical AI Expands US Presence with New Partnership Offering Its Breakthrough Real-Time Autonomous Medical Coding Solution

Leading National Medical Provider Achieves Contract to Live in Under 3 Months with 85% Direct-to-Bill…

1 hour ago

Apploi Announces Will Plourde as New Chief Technology Officer

NEW YORK, July 23, 2024 /PRNewswire/ -- Apploi, a leading provider of workforce solutions for…

1 hour ago

Clozd appoints John Thimsen to board of directors

Thimsen, who brings extensive experience leading product strategy at Amazon, Qualtrics, and Mason, joins the…

1 hour ago

THINK Surgical Receives FDA 510(k) Clearance for TMINI Miniature Robotic System (TMINI 1.1)

FREMONT, Calif., July 23, 2024 /PRNewswire/ -- THINK Surgical, Inc., an innovator in the field of…

1 hour ago